Henan Lingrui Pharmaceutical announced that the company's product, the Shenqi Lowering Sugar Capsules, is expected to be selected for the national Chinese Patent Medicine procurement alliance's centralized bulk purchasing. In 2023, the sales of this product were approximately 0.175 billion yuan, accounting for 5.28% of the company's revenue for the year 2023. From January to September 2024, the sales were approximately 0.166 billion yuan, accounting for 6.01% of the company's revenue for the first three quarters of 2024. Although the price of the selected product has decreased to some extent, it will be beneficial for the company to expand sales, increase market share, and enhance brand influence.